Hantavirus Vaccine Development Underway
Scientists are accelerating hantavirus vaccine development after a cruise ship outbreak, but face years of delays without major federal funding.
Objective Facts
On 7 May 2026, an international group of scientists at the University of Bath reported developing a hantavirus vaccine in response to the MV Hondius hantavirus outbreak. The team is led by Professor Asel Sartbaeva and uses mRNA technology combined with a patented 'Ensilication' technology that stabilizes vaccines by wrapping active ingredients in protective silica cages, allowing them to remain stable at ambient temperatures without refrigeration. Multiple vaccine development efforts are underway: Korea University's Vaccine Innovation Center and Moderna have been jointly developing an mRNA-based hantavirus vaccine since September 2023, with the candidate awaiting funding to begin human clinical trials, and Jay Hooper, a virologist at the US Army Medical Research Institute of Infectious Diseases, has been working for more than three decades to develop a vaccine against several species of hantavirus that can infect people, including the Andes virus. However, development timelines remain lengthy: EnsiliTech's vaccine hasn't entered human testing, estimating it could take three to four more years before early-stage clinical trials, and without Operation Warp Speed-style support, it could take five more years to complete Phase 2 and 3 trials. A critical obstacle is federal funding: in 2025, the Trump administration canceled funding for a pilot project studying the hantavirus, with all 10 Centers for Research in Emerging Infectious Diseases shut down, and the Trump administration has slashed millions of dollars' worth of research into mRNA vaccine technology.
Left-Leaning Perspective
Progressive outlets and public health experts heavily criticized the Trump administration's defunding of hantavirus research and broader mRNA vaccine development efforts. The Protect Our Care advocacy group framed the issue as reckless unpreparedness, stating that 'cutting the U.S. off from global crisis coordination that WHO offers while anti-vaxxer RFK Jr. guts domestic mRNA research has set the stage for an Operation Posthumous rather than Warp Speed-style vaccine development'. Rick Bright, former director of BARDA under the first Trump administration, told NPR that 'It is irresponsible to strip funding from future technologies with great potential and shift it towards outdated old-fashioned technologies...We're taking our country from 2025 back to 1940, and we all know that's a recipe for disaster and failure'. Scientific American detailed how in 2025 the Trump administration eliminated funding for a group that had been running a pilot project aimed at studying the type of hantavirus that has been confirmed to be behind an ongoing outbreak on a cruise ship. Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, warned Undark magazine that 'venture capital and pharma R&D dollars flow toward applications with clear commercial timelines' while 'Federal funding supports the foundational research,' and that 'we're already seeing private investors grow cautious, partly because the federal pullback signals political uncertainty around the technology'. Peter Hotez, dean of Baylor College of Medicine's National School of Tropical Medicine, told NPR that 'Many outside experts say Kennedy's claims are wrong' and 'His science is backwards, as it often is'. Left-leaning coverage emphasizes that hantavirus research suffered disproportionately from the administration's broader ideological skepticism toward mRNA platforms, arguing the cuts undermined pandemic preparedness regardless of whether any current hantavirus threat materializes. Progressive outlets downplay the rarity of hantavirus cases in the U.S. and instead focus on the 40-50% fatality rate of certain strains to argue for urgent federal investment.
Right-Leaning Perspective
The Trump administration and its supporters framed the mRNA research cuts as necessary fiscal discipline and a pivot toward safer alternatives. Health Secretary Robert F. Kennedy Jr. justified the policy by telling the public that the government was pulling $500 million 'to focus on safer, broader vaccine platforms,' with Kennedy claiming data showed mRNA vaccines 'fail to protect effectively against upper respiratory infections like COVID and flu'. The NIH statement defending the decision asserted that the canceled research 'has been deemed unsafe for Americans and not a good use of taxpayer funding'. Chris Meekins, a Raymond James analyst and former HHS strategic preparedness official under Trump, was quoted by Axios defending the technology's value, but the administration did not amplify critiques of its own policies in major right-leaning outlets. Right-leaning media coverage has largely been minimal on this specific vaccine development angle. The administration's position centers on skepticism about mRNA's effectiveness and a broader distrust of pandemic-era health bureaucracy. Republican operatives and certain conservative commentators have resisted the narrative that federal funding cuts undermine preparedness, instead emphasizing that some conservative-led states have targeted mRNA vaccines amid ongoing suspicion of public health officials and the tools they used to fight the COVID-19 pandemic. Right-leaning outlets have not prominently covered the University of Bath vaccine development or the broader international research efforts. Instead, conservative media focus has concentrated on conspiracy theories and vaccine skepticism, with figures like former Representative Marjorie Taylor Greene writing that pharmaceutical companies 'manipulate the virus, make the vaccine, and then make the profits'.
Deep Dive
Hantavirus vaccine development reveals a persistent tension between market economics and public health preparedness. Hantavirus vaccines are far from profitable—as a 'neglected infectious disease' occurring in rural areas and military bases, the market size is small and revenue projections are uncertain, giving companies little incentive to bear the hundreds of billions of won in clinical trial costs. This market failure has existed for decades. Jay Hooper at the US Army Medical Research Institute has spent more than three decades working on hantavirus vaccines, yet no vaccines have reached regulatory approval in the U.S. or Europe despite fatality rates reaching 50% in certain strains. The Trump administration's 2025 decision to eliminate mRNA research funding accelerated an existing problem. Government support for infectious disease R&D in South Korea had already declined from 661 billion won post-COVID to 434.3 billion won in 2024, with the share of infectious disease R&D dropping from 2.2% to 1.6%. The U.S. federal cuts to mRNA research compounds this global trend. However, the administration's framing—that it is shifting toward 'safer' platforms—is disputed by virologists who argue that mRNA's speed is its crucial advantage in pandemic contexts. The U.S. government provided $2.5 billion to Moderna and $1.9 billion to Pfizer, securing mRNA platform-based COVID-19 vaccines in about a year, while German and Japanese governments also obtained mRNA vaccines in 2023 after providing extensive support. Whether Operation Warp Speed-style funding could accelerate hantavirus vaccine timelines remains untested, but the absence of such support means the vaccine development timeline will extend from the current estimated 5-10 years. The cruise ship outbreak may shift political calculus, but current prediction markets price the probability of an approved vaccine by year-end 2026 at only 7.5%.
Regional Perspective
Korea University's Vaccine Innovation Center partnered with Moderna in September 2023 to develop an mRNA-based hantavirus vaccine, but producing clinical-grade material requires between 10-20 billion won (€6.5-13 million)—sums exceeding available budgets. South Korea's government support for infectious disease R&D declined from 661 billion won immediately after COVID-19 to 434.3 billion won in 2024, with the share of infectious disease R&D dropping from 2.2% to 1.6%. While mouse experiments confirmed protective efficacy of the mRNA hantavirus vaccine candidate, funding constraints have blocked human clinical trials, forcing researchers to wait for national project selection. Korea records 300 to 400 hantavirus cases annually, mostly among military personnel, creating immediate domestic urgency that global markets do not reflect. The University of Bath's vaccine development represents a different regional approach. The group is working with a Texas team that developed the hantavirus antigen and a South African company called Afrigen, applying thermal stabilization technology to make the vaccine resistant to temperature changes for drone deliveries. This reflects international collaboration centered in Europe but dependent on U.S. antigen development and African manufacturing partnerships. Regional media emphasis diverges from Western coverage primarily on funding urgency. South Korean field researchers point to the government's 'reactive support' approach as the root cause of recurring problems, noting that for infectious disease vaccines with low profitability, leaving development solely to the private sector inevitably creates gaps, making comprehensive government support essential. The Seoul Economic Daily focused on post-COVID funding collapse as a systemic problem, whereas Western outlets frame the Trump administration's 2025 cuts as the current crisis point. Regional outlets emphasize local disease burden—Korean cases primarily affecting military personnel—while Western coverage centers the cruise ship outbreak as the triggering event.